Hepatitis C and steatosis: a reappraisal
Authors:
- 7 December 2005
- journal article
- review article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 13 (2) , 73-80
Abstract
Summary. The overall prevalence of steatosis in patients with Hepatitis C virus (HCV) chronic infection is 55.5% (range 34.8–81.2%). This is a two to threefold increase compared with the prevalence of steatosis in chronic hepatitides because of other aetiologies and of the figures expected on the grounds of a steatosis–HCV chance association. HCV genotype 3 (HCV‐3) has specific epidemiological features; furthermore, as compared with HCV‐non‐3 genotypes, it is associated with a higher prevalence (74.1%vs47.9%,P < 0.01) and with more severe grades of steatosis (prevalence of grade 3 steatosis 29.6vs5.5P < 0.01). Host and viral factors play a role, although to a variable extent, in the pathogenesis of HCV‐3 and non‐3 steatosis. HCV load and body mass index are associated with steatosis in HCV‐3 and in HCV‐non‐3 patients respectively. Serum cholesterol levels and liver steatosis at baseline follow an inverse relationship in HCV infection. As hypocholesterolaemia corrects only in those sustained responders to antiviral treatment both in genotype 3 and in non‐3 genotypes, the occurrence of a virally induced, acquired and reversible hypobetalipoproteinaemia seems plausible. Steatosis affects the natural course of HCV infection: it is associated with fibrosis, a possible mediator of increased risk to develop type 2 diabetes, it impairs the response to antiviral treatment in HCV‐3 patients and might constitute a risk factor for the development of hepatocellular carcinoma. These observations indicate the need to evaluate the efficacy of combined antiviral and ‘metabolic’ approachesvsstandard antiviral regimes in patients with steatosis and HCV chronic infection.Keywords
This publication has 64 references indexed in Scilit:
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injuryHepatology, 2004
- Hepatitis C virus and liver steatosis: when fat is not beautifulJournal of Hepatology, 2004
- The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patientsJournal of Hepatology, 2004
- Obesity and Its Nurturing Effect on Hepatitis CHepatology, 2003
- Effect of Treatment With Peginterferon or Interferon Alfa–2B and Ribavirin on Steatosis in Patients Infected With Hepatitis CHepatology, 2003
- Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infectionCancer, 2003
- Hepatic steatosis in patients with chronic hepatitis C virus infectionCancer, 2003
- Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis CGut, 2002
- Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis CJournal of Clinical Pathology, 2001